Pharmacological inhibition of JNK, the sole downstream substrate of MAP2K7, with the selective JNK inhibitor JNK-IN-8 and other drugs tested in clinical trials showed anti-leukemic properties in T-ALL, validating the MAP2K7-JNK pathway as a therapeutic target. This evidence concerns the gene MAPK8 and acute lymphoblastic leukemia.